DNAJB11 and alpha 1-antitrypsin deficiency: Because we did not observe any indication of UPR or decreased cell viability with this treatment, silencing ERdj3 may be a promising therapeutic approach for liver disease caused by AATD‐related toxic gain of function in hepatocytes.